Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Mesa 2021 | Liquid vs solid tumor strategies in cell therapy

Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, provides an overview of the challenges in developing cell therapies in liquid and solid tumors. Whilst chimeric antigen receptor (CAR) T-cell therapies have been successful in B-cell malignancies such as myeloma, safety and cost issues as a result of T-cell expansion remain a barrier to widespread adoption. Further research is additionally required to enable the approval of cell therapies in other indications such as solid tumors and other B-cell malignancies including acute myeloid leukemia (AML). This interview took place at Meeting on the Mesa 2021.